Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Payables (2016 - 2025)

Ironwood Pharmaceuticals' Payables history spans 16 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Payables rose 36.25% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, up 36.25%, while the annual FY2025 figure was $2.9 million, 36.25% up from the prior year.
  • Payables for Q4 2025 was $2.9 million at Ironwood Pharmaceuticals, up from $1.6 million in the prior quarter.
  • Across five years, Payables topped out at $7.8 million in Q4 2023 and bottomed at $118000.0 in Q1 2023.
  • The 5-year median for Payables is $1.5 million (2025), against an average of $2.4 million.
  • The largest annual shift saw Payables plummeted 77.85% in 2021 before it soared 5172.88% in 2024.
  • A 5-year view of Payables shows it stood at $935000.0 in 2021, then plummeted by 48.34% to $483000.0 in 2022, then skyrocketed by 1521.12% to $7.8 million in 2023, then tumbled by 72.84% to $2.1 million in 2024, then soared by 36.25% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Payables are $2.9 million (Q4 2025), $1.6 million (Q3 2025), and $1.4 million (Q2 2025).